02256nas a2200469   4500000000100000000000100001008004100002260001200043653001200055653001100067653001300078653001100091653001400102653001600116653001000132653000900142653002400151100001700175700001700192700001600209700002100225700001700246700001700263700002000280700001900300700001800319700001700337700001600354700001500370700001800385700001300403700001900416700001600435700001900451700001800470700001900488245011000507300001300617490000600630520113600636022001401772       2021                            d  c2021-0410aAnimals10aFemale10aHormones10aHumans10aHydrogels10aOvariectomy10aOvary10aRats10aSpheroids, Cellular1 aHyo-Jin Yoon1 aYong Jae Lee1 aSewoom Baek1 aYoung Shin Chung1 aDae-Hyun Kim1 aJae Hoon Lee1 aYong Cheol Shin1 aYoung Min Shin1 aChungsoon Ryu1 aHye-Seon Kim1 aSo Hyun Ahn1 aHeeyon Kim1 aYoung Bin Won1 aInha Lee1 aMyung Jae Jeon1 aSi Hyun Cho1 aByung Seok Lee1 aHak-Joon Sung1 aYoung Sik Choi00aHormone autocrination by vascularized hydrogel delivery of ovary spheroids to rescue ovarian dysfunctions  aeabe88730 v73 aThe regeneration potential of implantable organ model hydrogels is applied to treat a loss of ovarian endocrine function in women experiencing menopause and/or cancer therapy. A rat ovariectomy model is used to harvest autologous ovary cells while subsequently producing a layer-by-layer form of follicle spheroids. Implantation of a microchannel network hydrogel with cell spheroids [vascularized hydrogel with ovarian spheroids (VHOS)] into an ischemic hindlimb of ovariectomized rats significantly aids the recovery of endocrine function with hormone release, leading to full endometrium regeneration. The VHOS implantation effectively suppresses the side effects observed with synthetic hormone treatment (i.e., tissue overgrowth, hyperplasia, cancer progression, deep vein thrombosis) to the normal levels, while effectively preventing the representative aftereffects of menopause (i.e., gaining fatty weight, inducing osteoporosis). These results highlight the unprecedented therapeutic potential of an implantable VHOS against menopause and suggest that it may be used as an alternative approach to standard hormone therapy.  a2375-2548